HOME >> BIOLOGY >> NEWS
'Cousin' Of Snake Venom Toxin Found In Mice

ily to which the gene belonged. "Nat and I sat down at the computer one day and tried to match lynx1's sequence of amino acids with those of known proteins. We did an exhaustive search of the database utilizing several different algorithms, then suddenly we got a hit," Miwa said. Relatively small but critically important sections within lynx1 matched the amino acid sequence of a snake toxin called alpha-bungarotoxin. This venom is a member of a large family of proteins called Ly-6. With that in mind, Heintz and Miwa named their gene "lynx," for Ly-6 neurotoxin.

"At that point we realized the potential significance of lynx1," Miwa said. "Bungarotoxin was known to bind to acetylcholine receptors, so if lynx1 could bind to these receptors too, it might be important for brain signaling."

Ines Ibanez-Tallon, an HHMI associate in Heintz's lab, localized the nerve cell receptors with which lynx1 interacts, and showed that the distribution of these receptors is similar to that of acetylcholine receptors in the cerebellum, a region of the brain involved in controlling motion and motor learning.

Additional collaborators in Lorna Role's laboratory at Columbia University tested lynx1's effect on frog eggs (or oocytes) that had been injected with acetylcholine receptors. Miwa said the eggs' acetylcholine response was 30 percent larger after bathing them with lynx1, suggesting that lynx1 might enhance the action of acetylcholine. By contrast, its cousin, alpha-bungarotoxin, interferes with acetylcholine's activity. But many drugs that affect the brain have been found to generate effects opposite to those of similar substances produced by brain tissue, Heintz said.

Acetylcholine receptors are thought to be involved in memory and in the pathogenesis of Alzheimer's disease, where loss of inputs from acetylcholine neurons is a hallmark of the disease. "If lynx1 acts in the whole animal like it does in cells, then the structure of the p
'"/>

Contact: Jim Keeley
keeleyj@hhmi.org
301-215-8858
Howard Hughes Medical Institute
28-May-1999


Page: 1 2 3

Related biology news :

1. Snakehead in your inbox? Welcome to the nonindigenous Aquatic Species Alert System
2. Controlling Problem Snakes: Saipan Benefits From USGS Research
3. A Real Smart Asp: Snakes Show Surprising Ability To Learn
4. Experimental Drug Derived From Snake Venom Shows Promise In Reversing Effects Of Stroke
5. Snake Venom Slows Tumor Growth
6. Venom hunt finds harmless snakes a potential danger
7. Venomous dinosaurs really existed
8. Spider Venom Stops Stroke Brain Damage
9. Salve From Serpents? UD Studies May Explain Why Viper-Venom Protein Stops Tumor Spread In Mice
10. Toxin combo common in fish appears capable of impairing motor skills
11. Symposium Probes Impact Of Toxins On Development

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cousin Snake Venom Toxin Found Mice

(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
(Date:10/17/2014)... release is available in German . ... of sperms every day in order to reproduce? And why ... the topic of the latest issue of the research journal ... The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has ... is not unusual for a female to copulate with several ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
Cached News: